Herceptin is a recombinant humanized monoclonal antibody against HER2/Neu receptor, which is the first line treatment for Her2 + breast cancer patients and thus of general interest (De Mattos-Arruda & Cortes, 2012). Here, ERBB2 is linked to breast carcinoma.